San Diego-dependent Viking Therapeutics marked itself as a significant competitor while in the weight loss drug sector in February following revealing promising information from the mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the